Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease

Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease

The prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D.This article explores the various trials already performed and under development in this field, with...

Full description

Bibliographic Details
Main Authors:	Pedro Monteiro, Carlos Aguiar, Pedro Matos, José Silva-Nunes, Rita Birne, Patrícia Branco, Joaquim Calado, Miguel Melo, Jorge Polónia
Format:	Article
Language:	English
Published:	Elsevier 2019-10-01
Series:	Revista Portuguesa de Cardiologia (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2174204919302879

Similar Items

Efeito da empagliflozina para além do controlo glicémico: benefício cardiovascular em doentes com DMT2 e doença cardiovascular estabelecida
by: Pedro Monteiro, et al.
Published: (2019-10-01)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
by: Mafalda Ramos, et al.
Published: (2021-08-01)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
by: Atsushi Tanaka, et al.
Published: (2021-07-01)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01)

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
by: EMPA-REG OUTCOME Investigators, et al.
Published: (2018)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
by: Odette S Reifsnider, et al.
Published: (2021-08-01)

Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality
by: PURE Study Investigators, et al.
Published: (2021)

Glycemic index, glycemic load, and cardiovascular disease and mortality
by: Alhabib, K.F, et al.
Published: (2021)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial
by: Takashi Kadowaki, et al.
Published: (2019-05-01)

Budget impact analysis of empagliflozin in T2D patients with a previous cardiovascular disease
by: Sergio Iannazzo, et al.
Published: (2017-06-01)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017-05-01)

The Role of Glycemic Variability in Cardiovascular Disorders
by: Valentina Alfieri, et al.
Published: (2021-08-01)

Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA (R)
by: EMPA-REG OUTCOME Investigato, et al.
Published: (2018)

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome
by: Mahmoud Elrouby, et al.
Published: (2017-10-01)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
by: George, J.T, et al.
Published: (2021)

Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
by: Darren K. McGuire, et al.
Published: (2021-04-01)

Cost-effectiveness analysis of empagliflozin in the treatment of patients with type 2 diabetes and established cardiovascular disease in Italy, based on the results of the EMPA-REG OUTCOME study
by: Sergio Iannazzo, et al.
Published: (2017-10-01)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
by: Atsushi Tanaka, et al.
Published: (2020-11-01)

Association between glycemic index, glycemic load and cardiovascular risk factors in adults
by: Hosseinpour-Niazi S, et al.
Published: (2013-04-01)

Relevance of the Glycemic Index and Glycemic Load for Body Weight, Diabetes, and Cardiovascular Disease
by: Sonia Vega-López, et al.
Published: (2018-09-01)

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
by: Yutaka Seino, et al.
Published: (2021-01-01)

Revisiting clinical trials on glycemic control and cardiovascular risk
by: Ferreira Sandra
Published: (2009-09-01)

The Impact of Dietary Glycemic Index and Glycemic Load on Postprandial Lipid Kinetics, Dyslipidemia and Cardiovascular Risk
by: Vaia Lambadiari, et al.
Published: (2020-07-01)

Cardiovascular benefits of exercise
by: Agarwal SK
Published: (2012-06-01)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
by: Annayya R. Aroor, et al.
Published: (2018-07-01)

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
by: Dimitrios Patoulias, et al.
Published: (2018-12-01)

Sodium glucose co-transporter-2 inhibitor: Benefits beyond glycemic control
by: Manash Pratim Baruah, et al.
Published: (2019-01-01)

Glycemic variability and cardiovascular disease in patients with type 2 diabetes
by: Guillermo E Umpierrez, et al.
Published: (2021-08-01)

Hemorheological and Glycemic Parameters and HDL Cholesterol for the Prediction of Cardiovascular Events
by: Sung Woo Cho, et al.
Published: (2016-01-01)

Glycemic index and glycemic load are associated with some cardiovascular risk factors among the PREMIER study participants
by: Pao-Hwa Lin, et al.
Published: (2012-06-01)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
by: Men P, et al.
Published: (2020-08-01)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes.
by: Bruce A Perkins, et al.
Published: (2015-01-01)

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
by: Hanefeld Markolf
Published: (2007-08-01)

Cardiovascular Effects and Benefits of Exercise
by: Matthew A. Nystoriak, et al.
Published: (2018-09-01)

Tight glycemic control and cardiovascular effects in type 2 diabetic patients
by: Latha Subramanya Moodahadu, et al.
Published: (2014-01-01)

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?
by: Miguel Melo, et al.
Published: (2021-07-01)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial
by: EMPA-REG OUTCOME Trial, et al.
Published: (2016)

Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
by: Antonio Ceriello, et al.
Published: (2020-10-01)

Effect of Diets Differing in Glycemic Index and Glycemic Load on Cardiovascular Risk Factors: Review of Randomized Controlled-Feeding Trials
by: Alice H. Lichtenstein, et al.
Published: (2013-03-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)